Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WESTLAKE VILLAGE, Calif. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of common stock at a public offering price of $15.00 per share, which includes the exercise in full by
Toggle Summary Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
WESTLAKE VILLAGE, Calif. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today reported the Company’s financial results for the second quarter of 2017. “We are pleased to report the results of our second quarter,” said Frederick C.
Toggle Summary Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA ) today announced the pricing of the Company’s initial public offering of 4,333,333 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts.

SEC Filings

Events

There are currently no events to display.

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Cowen
Ken Cacciatore
BMO Capital Markets
Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

Wells Fargo Shareowner Services
www.shareowneronline.com

IR Contact

IR@SiennaBio.com

Media Contact

media@SiennaBio.com